Romiplostim: Thrombopoietin receptor ligand antithrombocytopenic agent treatment of idiopathic thrombocytopenic purpura

Drugs of the Future

Volumn 32, Issue 9, 2007, Pages 781-787

  Provan, Drew ^a   Newland, Adrian C ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMG 531; ANTINEOPLASTIC AGENT; ANTITHROMBOCYTIC AGENT; CORTICOSTEROID; HUMAN IMMUNOGLOBULIN; PLACEBO; RECOMBINANT THROMBOPOIETIN; ROMIPLOSTIM; THROMBOPOIETIN; THROMBOPOIETIN RECEPTOR; UNCLASSIFIED DRUG; VINCA ALKALOID;

ARTHRALGIA; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTUSION; DISEASE EXACERBATION; DOSE RESPONSE; DRUG APPROVAL; DRUG BINDING; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPISTAXIS; FATIGUE; HEADACHE; HEPATITIS C; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOSUPPRESSIVE TREATMENT; MORBIDITY; MORTALITY; MYELODYSPLASIA; NONHUMAN; PETECHIA; SIDE EFFECT; SPLENECTOMY; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOCYTOPOIESIS; THROMBOCYTOSIS;

EID: 36348981066     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2007.032.09.1135519     Document Type: Article

References (54)

1. de Sauvage, F.J., Hass, P.E., Spencer, S.D. et al. Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. Nature 1994, 369(6481): 533-8.
2. Kuter, D.J., Beeler, D.L., Rosenberg, R.D. The purification of megapoietin: A physiological regulator of megakaryocyte growth and platelet production. Proc Natl Acad Sci USA 1994, 91(23): 11104-8.
3. Lok, S., Kaushansky, K., Holly, R.D. et al. Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature 1994, 369(6481): 565-8.
4. Briddell, R.A., Bruno, E., Cooper, R.J., Brandt, J.E., Hoffman, R. Effect of c-kit ligand on in vitro human megakaryocytopoiesis. Blood 1991, 78(11): 2854-9.
5. Debili, N., Masse, J.M., Katz, A., Guichard, J., Breton-Gorius, J., Vainchenker, W. Effects of the recombinant hematopoietic growth factors interleukin-3, interleukin-6, stem cell factor, and leukemia inhibitory factor on the megakaryocytic differentiation of CD34+ cells. Blood 1993, 82(1): 84-95.
6. Kaushansky, K. Thrombopoietin. New Engl J Med 1998, 339(11): 746-54.
7. Kelemen, E., Cserhati, I., Tanos, B. Demonstration and some properties of human thrombopoietin in thrombocythaemic sera. Acta Haematol 1958, 20(6): 350-5.
8. Bartley, T.D., Bogenberger, J., Hunt, P. et al. Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl. Cell 1994, 77(7): 1117-24.
9. Sohma, Y., Akahori, H., Seki, N. et al. Molecular cloning and chromosomal localization of the human thrombopoietin gene. FEBS Lett 1994, 353(1): 57-61.
10. Methia, N., Louache, F., Vainchenker, W., Wendling, F. Oligodeoxynucleotides antisense to the proto-oncogene c-mpl specifically inhibit in vitro megakaryocytopoiesis. Blood 1993, 82(5): 1395-401.
11. Debili, N., Wendling, F., Katz, A., Guichard, J., Breton-Gorius, J., Hunt, P., Vainchenker, W. The Mpl-ligand or thrombopoietin or megakaryocyte growth and differentiative factor has both direct proliferative and differentiative activities on human megakaryocyte progenitors. Blood 1995, 86(7): 2516-25.
12. Nichol, J.L. The Mpl ligand and platelet homeostasis. Acta Paediatr Suppl 1998, 424: 7-15.
13. Kaushansky, K. The molecular mechanisms that control thrombopoiesis. J Clin Invest 2005, 115(12): 3339-47.
14. Bouscary, D., Lecog-Lafon, C., Chretien, S. et al. Role of Gab proteins in phosphatidylinositol 3-kinase activation by thrombopoietin (Tpo). Oncogene 2001, 20(18): 2197-204.
15. Miyakawa, Y., Rojnuckarin, P., Habib, T., Kaushansky, K. Thrombopoietin induces phosphoinositol 3-kinase activation through SHP2, Gab, and insulin receptor substrate proteins in BAF3 cells and primary murine megakaryocytes. J Biol Chem 2001, 276(4): 2494-502.
16. Drachman, J.G., Sabath, D.F., Fox, N.E., Kaushansky, K. Thrombopoietin signal transduction in purified murine megakaryocytes. Blood 1997, 89(2): 483-92.
17. Kirito, K., Fox, N., Kaushansky, K. Thrombopoietin stimulates Hoxb4 expression: an explanation for the favorable effects of TPO on hematopoietic stem cells. Blood 2003, 102(9): 3172-8.
18. van Willigen, G., Gorter, G., Akkerman, J.W. Thrombopoietin increases platelet sensitivity to alpha-thrombin via activation of the ERK2-cPLA2 pathway. Thromb Haemost 2000, 83(4): 610-6.
19. Qian, S., Fu, F., Li, W., Chen, Q., de Sauvage, F.J. Primary role of the liver in thrombopoietin production shown by tissue-specific knockout. Blood 1998, 92(6): 2189-91.
20. Stoffel, R., Wiestner, A., Skoda, R.C. Thrombopoietin in thrombocytopenic mice: Evidence against regulation at the mRNA level and for a direct regulatory role of platelets. Blood 1996, 87(2): 567-73.
21. Yang, C., Li, Y.C., Kuter, D.J. The physiological response of thrombopoietin (c-Mpl ligand) to thrombocytopenia in the rat. Br J Haematol 1999, 105(2): 478-85.
22. McCarty, J.M., Sprugel, K.H., Fox, N.E., Sabath, D.E., Kaushansky, K. Murine thrombopoietin mRNA levels are modulated by platelet count. Blood 1995, 86(10): 3668-75.
23. Ulich, T.R., del Castillo, J., Senaldi, G. et al. Systemic hematologic effects of PEG-rHuMGDF-induced megakaryocyte hyperplasia in mice. Blood 1996, 87(12): 5006-15.
24. Cines, D.B., Blanchette, V.S. Immune thrombocytopenic purpura. New Engl J Med 2002, 346(13): 995-1008.
25. Stasi, R., Provan, D. Management of immune thrombocytopenic purpura in adults. Mayo Clin Proc 2004, 79(4): 504-22.
26. Ballem, P.J., Segal, G.M., Stratton, J.R., Gernsheimer, T., Adamson, J.W., Slichter, S.J. Mechanisms of thrombocytopenia in chronic autoimmune thrombocytopenic purpura. Evidence of both impaired platelet production and increased platelet clearance. J Clin Invest 1987, 80(1): 33-40.
27. Berchtold, P., McMillan, R. Therapy of chronic idiopathic thrombocytopenic purpura in adults. Blood 1989, 74(7): 2309-17.
28. Blanchette, V., Freedman, J., Garvey, B. Management of chronic immune thrombocytopenic purpura in children and adults. Semin Hematol 1998, 35(1, Suppl. 1): 36-51.
29. Chong, B.H. Diagnosis, treatment and pathophysiology of autoimmune thrombocytopenias. Crit Rev Oncol Hematol 1995, 20(3): 271-96.
30. Ikehara, S., Mizutani, H., Kurata, Y. Autoimmune thrombocytopenic purpura. Crit Rev Oncol Hematol 1995, 19(1): 33-45.
31. Karpatkin, S. Autoimmune (idiopathic) thrombocytopenic purpura. Lancet 1997, 349(9064): 1531-6.
32. Semple, J.W., Freedman, J. Abnormal cellular immune mechanisms associated with autoimmune thrombocytopenia. Transfus Med Rev 1995, 9(4): 327-38.
33. Wang, Z.Y., Shen, Z.X. Megakaryocytes and platelets in immune thrombocytopenic purpura. Baillieres Clin Haematol 1997, 10(1): 89-107.
34. Yang, R., Han, Z.C. Pathogenesis and management of chronic idiopathic thrombocytopenic purpura: An update. Int J Hematol 2000, 71(1): 18-24.
35. Lechner, K. Management of adult immune thrombocytopenia. Rev Clin Exp Hematol 2001, 5(3): 222-35.
36. George, J.N., Woolf, S.H., Raskob, G.E. et al. Idiopathic thrombocytopenic purpura: A practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996, 88(1): 3-40.
37. British Committee for Standards in Haematology General Haematology Task Force. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol 2003, 120(4): 574-96.
38. Portielje, J.E., Westendorp, R.G., Kluin-Nelemans, H.C., Brand, A. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood 2001, 97(9): 2549-54.
39. Nomura, S., Dan, K., Hotta, T., Fujimura, K., Ikeda, Y. Effects of pegylated recombinant human megakaryocyte growth and development factor in patients with idiopathic thrombocytopenic purpura. Blood 2002, 100(2): 728-30.
40. Li, J., Yang, C., Xia, Y., Bertino, A., Glaspy, J., Roberts, M., Kuter, D.J. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 2001, 98(12): 3241-8.
41. Basser, R.L., O'Flaherty, E., Green, M. et al. Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor. Blood 2002, 99(7): 2599-602.
42. Kuter, D.J., Begley, C.G. Recombinant human thrombopoietin: Basic biology and evaluation of clinical studies. Blood 2002, 100(10): 3457-69.
43. Kuter, D.J. New thrombopoietic growth factors. Blood 2007, 109(11): 4607-16.
44. Wang, B., Nichol, J.L., Sullivan, J.T. Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin Pharmacol Ther 2004, 76(6): 628-38.
45. Bussel, J.B., Kuter, D.J., George, J.N. et al. AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. New Engl J Med 2006, 355(16): 1672-81.
46. Rice, L. Drug evaluation: AMG-531 for the treatment of thrombocytopenias. Curr Opin Invest Drugs 2006, 7(9): 834-41.
47. Broudy, V.C., Lin, N.L. AMG531 stimulates megakaryopoiesis in vitro by binding to Mpl. Cytokine 2004, 25(2): 52-60.
48. Sun, Y., Arends, R., Smithson, A., Watson, A., Nichol, J.L. A novel thrombopoiesis-stimulating agent, AMG-531: Pharmacokinetics and pharmacodynamics in FcRn knock-out and wild-type mice. Blood 2005, 106(11): Abst 3575.
49. Douglas, V.K., Tallman, M.S., Cripe, L.D., Peterson, L.C. Thrombopoietin administered during induction chemotherapy to patients with acute myeloid leukemia induces transient morphologic changes that may resemble chronic myeloproliferative disorders. Am J Clin Pathol 2002, 117(6): 844-50.
50. Kuter, D.J., Goodnough, L.T., Romo, J. et al. Thrombopoietin therapy increases platelet yields in healthy platelet donors. Blood 2001, 98(5): 1339-45.
51. Vadhan-Raj, S., Murray, L.J., Bueso-Ramos, C. et al. Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer. Ann Intern Med 1997, 126(9): 673-81.
52. Basser, R.L., Rasko, J.E., Clarke, K. et al. Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer. Lancet 1996, 348(9037): 1279-81.
53. Newland, A., Caulier, M.T., Kappers-Klunne, M. et al. An open-label, unit dose-finding study of AMG 531, a novel thrombopoiesis-stimulating peptibody, in patients with immune thrombocytopenic purpura. Br J Haematol 2006, 135(4): 547-53.
54. Kuter, D., Bussel, J., George, J. et al. Long-term dosing of AMG 531 in thrombocytopenic patients with immune thrombocytopenic purpura: 48-Week update. Blood 2006, 108(11): Abst 476.